fusion inhibitor


Also found in: Dictionary, Wikipedia.
Related to fusion inhibitor: protease inhibitor, Integrase inhibitor

fusion inhibitor

a drug that prevents sufficient joining of viral and host cell membranes for infection to occur.

fusion inhibitor

n.
Any of a class of drugs that interfere with the entry of HIV into helper T cells by inhibiting the fusion of the viral and cell membranes.
References in periodicals archive ?
Anti-HIV-1 agents known as fusion inhibitors target the N-HR or C-HR and disrupt their association, which prevents the virus from entering into the host cell.
Many of the patients had been taking a fusion inhibitor called T-20, an experimental drug that will probably be approved for use soon by FDA, Miralles says.
The entry inhibitor category includes the fusion inhibitor class, as well as two other classes: attachment inhibitors and co-receptor inhibitors.
Approved by the FDA in March 2003, FUZEON is the first and only fusion inhibitor for the treatment of HIV and works in a way that is different from other types of anti-HIV drugs.
Roche and Trimeris currently market FUZEON(R) (enfuvirtide), the first and only fusion inhibitor available for the treatment of HIV.
Classes of entry inhibitors include coreceptor inhibitors (these block HIV's interaction with coreceptors such as the chemokines CCR5 and CXCR4) and fusion inhibitors (these prevent the virus from fusing with the cell membrane).
today announced the selection of two next-generation fusion inhibitor peptides for co-development and progression into further pre- clinical studies.
China's FusoGen Pharmaceuticals has developed a new HIV fusion inhibitor that is currently in human clinical trials.
Only one fusion inhibitor has been approved so far, and this particular drug is expensive to manufacture and difficult to use.
The difference between the fusion inhibitor group and the control groups was statistically significant, reported Dr.
Under this agreement, all rights and joint patents and other intellectual property rights to the next generation fusion inhibitor peptides falling under the Research Agreement, which includes our lead drug candidate, TRI-1144, reverted to Trimeris.